Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Election of Directors
On July 9, 2014
, J. Craig Venter
, Ph.D. joined the Board of Directors (the
"Board") of MYOS Corporation
(the "Company"). The Board has not determined on
which committees of the Board Dr. Venter will serve.
Dr. Venter has more than 30 years of scientific leadership and entrepreneurial
biotechnology expertise, and is world-renowned for sequencing the first draft
human genome, the first complete human genome and constructing the first
synthetic cell. In 1992, he founded and led The Institute for Genomic Research
(TIGR), a not-for-profit genomics focused research institute. In 2006, TIGR and
several other not-for-profits founded by Dr. Venter merged to become the J.
Craig Venter Institute
(JCVI) where he serves as Chairman and Chief Executive
Officer. Dr. Venter and his team at JCVI have sequenced thousands of genomes
beginning with the genome of the first free-living organism, the bacterium
Haemophilus influenza in 1995. Since 2013, Dr. Venter has served as a co-founder
and Chief Executive Officer of Human Longevity, Inc.
, a privately-held genomics
and cell therapy-based diagnostic and therapeutic company focused on extending
the healthy, high performance human life span. Since 2005, Dr. Venter has served
as Founder and Chief Executive Officer of Synthetic Genomics Inc.
privately-held company dedicated to commercializing genomic-driven solutions to
address global needs such as new sources of energy, new food and nutritional
products, and next generation vaccines. From 1998 to 2002, Dr. Venter served as
co-founder and Chief Executive Officer of Celera Genomics, a publicly traded
company that utilized the cutting-edge tools and techniques he and his team
developed to successfully sequence and publish the first draft human genome as
well as other model organisms including the fruit fly, mouse and rat genomes.
From 1984 to 1992, he conducted research at the National Institutes of Health
where he developed Expressed Sequence Tags or ESTs, a new strategy for rapid
gene discovery. From 1976 to 1984, Dr. Venter served as professor at the State
University of New York at Buffalo
and the Roswell Park Cancer Institute
Venter earned both a Bachelor's degree in Biochemistry and a PhD in Physiology
and Pharmacology from the University of California at San Diego
Dr. Venter is the author of more than 250 research articles. He is also the
recipient of numerous honorary degrees, public honors, and scientific awards,
including the 2008 United States National Medal of Science, the 2002 Gairdner
Award and the 2001 Paul Ehrlich and Ludwig Darmstaedter
Prize. Dr. Venter is a member of numerous prestigious scientific organizations
including the National Academy of Sciences
, the American Academy of Arts and
and the American Society for Microbiology
. Dr. Venter has published two
books, his autobiography A Life Decoded (2007), and Life at the Speed of Light
(2013), which examines the history of microbiology and future application of
Item 8.01 Other Events.
On July 9, 2014
, the Company issued a press release announcing that its common
stock had been approved for listing on the NASDAQ Capital Market
, and that it
expects to commence trading under its current symbol "MYOS" on July 10, 2014
copy of the press release is attached hereto as Exhibit 99.1.
On July 14, 2014
, the Company issued a press release announcing the appointment
of Dr. Venter. A copy of the press release is attached hereto as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press release issued by the Company on July 9, 2014
99.2 Press release issued by the Company on July 14, 2014